Onconetix (FRA:J4T) Other Current Payables: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:J4T Onconetix Inc FRA:J4T
19 GF Score
Price €11,985.00
! 4 Warning Signs
View Full Analysis

What is Onconetix Other Current Payables?

Onconetix FRA:J4T 19 Other Current Payables is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:J4T with a GF Score™ of 19/100. The stock has 4 warning signs investors should review.

Onconetix's Other Current Payables for the quarter that ended in Mar. 2026 was €0.00 Mil.

Onconetix's quarterly Other Current Payables increased from Sep. 2025 (€0.00 Mil) to Dec. 2025 (€0.00 Mil) but then declined from Dec. 2025 (€0.00 Mil) to Mar. 2026 (€0.00 Mil).

Onconetix's annual Other Current Payables increased from Dec. 2023 (€-0.00 Mil) to Dec. 2024 (€3.94 Mil) but then declined from Dec. 2024 (€3.94 Mil) to Dec. 2025 (€0.00 Mil).

Onconetix Other Current Payables Related Terms

Onconetix Other Current Payables Historical Data

* Premium members only.

The historical data trend for Onconetix's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Onconetix Other Current Payables Chart

Onconetix Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial 0.00 0.00 -0.00 3.94 0.00

Onconetix Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.11 0.35 0.00 0.00 0.00
FRA:J4T
19GF Score
Onconetix Inc FRA:J4T
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Onconetix Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of €0.00 Mil mean?
Onconetix (FRA:J4T) has a Other Current Payables of €0.00 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Onconetix and its competitors.
Is Onconetix's Other Current Payables too high?
Onconetix's current Other Current Payables is €0.00 Mil. Overall, Onconetix has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Onconetix's Other Current Payables compare to CMND and REVB?
Onconetix's Other Current Payables of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Onconetix and its competitors. Onconetix's current Other Current Payables is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Onconetix stock overvalued right now?
Onconetix (FRA:J4T) has a current Other Current Payables of €0.00 Mil. The current Other Current Payables is €0.00 Mil. Onconetix's overall GF Score™ is 19/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Onconetix (FRA:J4T), the current Other Current Payables is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Onconetix Business Description

Other Exchanges ONCO:USA
Address 201 E. Fifth Street, Suite 1900, Cincinnati, OH, USA, 45202
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
19GF Score

Get the complete analysis for FRA:J4T

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11,985.00
Price